|Year : 2017 | Volume
| Issue : 2 | Page : 445-446
Candidate for a live vaccine?
Justin Ralph Abbatemarco1, Alan Taege2
1 Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
2 Department of Infectious Disease, Cleveland Clinic Foundation, Cleveland, Ohio, USA
|Date of Web Publication||7-Dec-2017|
Dr. Justin Ralph Abbatemarco
Cleveland Clinic, 9500 Euclid Ave S100A, Cleveland, OH 44195
Source of Support: None, Conflict of Interest: None
Immune dysfunction is a well-known phenomenon in end-stage liver disease (ESLD). The pretransplant period offers a unique window for primary care physicians to optimize the transplant's vaccine protection before antirejection medications are initiated. Live vaccinations are selected cautiously but the varicella-zoster virus (VZV) vaccine, Zostavax, is recommended for pretransplant candidates. This case highlights an ESLD patient who developed disseminated cutaneous VZV within 30 days of vaccination.
Keywords: Cirrhosis-associated immune deficiency, disseminated cutaneous varicella zoster, end-stage liver disease, liver transplantation, Zostavax vaccine
|How to cite this article:|
Abbatemarco JR, Taege A. Candidate for a live vaccine?. J Family Med Prim Care 2017;6:445-6
| Introduction|| |
Vaccines serve as cornerstone for disease prevention in the primary care setting. This potential benefit is even more apparent in certain high-risk population such as immunosuppressed patients or potential transplant patients who will be committed to life-long immune altering medications. Primary care physicians are confronted with the risk/benefit of administering live vaccines in these susceptible populations. This paper specifically dissects a case involving an end-stage liver disease (ESLD) patient who developed disseminated cutaneous varicella-zoster virus (VZV) within 30 days of vaccination.
| Case Report|| |
A 66-year-old Caucasian male with ESLD secondary to alcoholic cirrhosis was admitted for an elective transjugular intrahepatic portosystemic shunt procedure. During his transplant evaluation 2 months earlier, the patient's HIV, Hepatitis A, B, and C serologies were negative. His VZV IgG level at 3135 (>165 index value) was consistent with past infection. There was no history of diabetes mellitus or renal dysfunction, and the patient was not using immunosuppressive medications. The Zostavax vaccine (live, attenuated Oka/Merck VZV strain) was administered approximately 1 month before this admission.
After the procedure, the patient developed a pruritic rash on his back without prodromal features. The rash featured vesicular lesions over an erythematous base that was confined to the T1 dermatome and did not cross midline. Over the course of 5 days, the rash spread to his head and neck. Subsequently, it spread to his entire body, sparing the mucosal surfaces.
A direct fluorescent VZV antibody stain taken from a vesicle was positive. Treatment was initiated with intravenous Acyclovir 10 mg/kg every 8 h for disseminated cutaneous VZV infection. A 7 day course was completed, and the patient's lesions resolved.
| Discussion|| |
VZV infection has a bimodal age distribution. The first outbreak usually occurs between 1 and 9 years of age, leading to active varicella (chickenpox) infection. The virus lays dormant within the dorsal root ganglia and reactivates to produce dermatomal VZV infection. In 6%–30% of immunocompromised patients, the reactivated virus can cause disseminated cutaneous VZV infection, defined by the presence of more than 20 vesicular lesions that do not follow dermatomal patterns, and crosses the midline boundary. This cutaneous outbreak can lead to life-threatening, multi-organ involvement including encephalitis, meningitis, pneumonitis, or myocarditis.
ESLD is known to cause cirrhosis-associated immune deficiency. Liver dysfunction leads to diminished synthetic production of complement proteins, pattern-recognition receptors, and acute phase reactants. This impaired response to pathogens is combined with a paradoxical, chronic systemic inflammatory state due to immune cell upregulation of cytokine production (specifically tumor necrosis factor-α), and surface activation markers.
The recent Zostavax administration in context of the cutaneous eruption is interesting. The patient's titers were consistent with past infection and should have conferred some protection. A study of over 14,000 patients who were taking immunosuppressive medications and who received the vaccine showed no link to disseminated VZV outbreak. However, several reports describe disseminated VZV related to the Oka VZV strain. The outbreaks usually occur within 42 days of vaccination. Our patient's vaccination was within 30 days of his outbreak.
It is difficult to ascertain whether the outbreak was due to the vaccine or reactivation of native virus, but the timing of events certainly raises that clinical question. The alteration in cell-mediated immunity in ESLD may explain the underlying pathophysiology and give healthcare providers pause when interpreting prevaccination titers. This leads us to the timing of live vaccinations in the pretransplant workup and potential risk associated with vaccination. Fortunately, a new recombinant subunit vaccine has successfully completed a phase three trial and may be an important alternative to live VZV vaccination.
To the best of our knowledge, there are no reports of disseminated cutaneous VZV infection in ESLD.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al
. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44-100.
Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: Clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 2008;26:675-97, viii.
Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al.
Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc 2015;90:865-73.
Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, et al.
The safety profile of varicella vaccine: A 10-year review. J Infect Dis 2008;197 Suppl 2:S165-9.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al.
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087-96.